Cart
sales@molnova.com
Sibeprenlimab
CAS No. 2382896-07-1
Sibeprenlimab( —— )
Catalog No. M36868 CAS No. 2382896-07-1
Sibeprenlimab (VIS649) is a humanized IgG2 monoclonal antibody that inhibits APRIL and may be investigated for the prevention and treatment of kidney disease (IgAN).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 588 | In Stock |
|
| 10MG | 938 | In Stock |
|
| 25MG | 1387 | In Stock |
|
| 50MG | 1832 | In Stock |
|
| 100MG | 2474 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameSibeprenlimab
-
NoteResearch use only, not for human use.
-
Brief DescriptionSibeprenlimab (VIS649) is a humanized IgG2 monoclonal antibody that inhibits APRIL and may be investigated for the prevention and treatment of kidney disease (IgAN).
-
DescriptionSibeprenlimab (VIS649) is a humanized IgG2 monoclonal antibody. Sibeprenlimab can inhibit APRIL. Sibeprenlimab can be used for the research of IgA nephropathy (IgAN).
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2382896-07-1
-
Formula Weight
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
-
Thalidomide-5-OH
Thalidomide-5-OH is the Thalidomide-based cereblon ligand that used in the recruitment of CRBN protein. It can be connected to the ligand for protein by a linker to form PROTAC.
-
Nemvaleukin alfa
Nemvaleukin alfa (ALKS 4230) is an interleukin 2 fusion protein, a selective agonist of the medium-affinity IL-2 receptor, produced by fusion of the IL-2Ralpha subunit of the circularly arranged interleukin-2 (IL-2) and IL-2 receptor (IL-2R) complexes, which drives antitumor Immunity and inhibits tumor growth in small cell lung cancer.
-
Letaplimab
Letaplimab (IBI-188) is a humanized IgG4 class antibody targeting CD47 and is often used in combination with azacitidine for the treatment of primary diagnosis of intermediate- to high-risk myelodysplastic syndromes.
